HOME >> MEDICINE >> NEWS
Online calculator and chemotherapy order systems reduce medication errors in children

Two new studies from the Johns Hopkins Children's Center show that computerizing ordering of chemotherapy and other types of intravenous drug infusions for children greatly reduces the risk of potentially dangerous medical errors.

An online infusion calculator and a computerized drug ordering system, developed under the leadership of Christoph Lehmann, M.D., director of clinical information technology at the Children's Center, have been in use there for about three years, but this is the first time that researchers have measured their impact on medication errors.

Children in general are three times more likely than adults to be victims of medication errors because both ordering and dosing are more complex in children than adults, according to Lehmann. In children, dosing is based on calculations factoring in age, height and weight, and miscalculations and rounding errors could cause life-threatening harm. Dosing errors also cause more ill effects in children because still-developing bodies absorb, metabolize and excrete drugs at different rates than adults and thus have lower tolerance for medication overdose. Children undergoing treatment for cancer are at even greater risk because the general dangers of potent chemicals are compounded by the dosing challenges.

"Our findings reveal that using a Web-based calculator makes it less likely to order and give a child the wrong dose or commit other errors, such as omitting patient information, weight parameters or infusion rates," explains Lehmann, lead author of the Web-based calculator study, which appears in the May 8 issue of Pediatric Critical Care Medicine. "Our calculator stops ordering errors before they can even reach the pharmacy, let alone the patient."

The calculator computes all doses, advises and warns of drug interactions and automatically offers "default" doses and drug dilutions to help doctors avoid overdosing and under-dosing.

For the study, researchers compar
'"/>

Contact: Katerina Pesheva
epeshev1@jhmi.edu
410-516-4996
Johns Hopkins Medical Institutions
8-May-2006


Page: 1 2 3 4

Related medicine news :

1. Online education program better source of information for patients
2. Online book helps children understand the effects of stroke
3. Online ear and hearing diagnosis to break sound barrier
4. Online analytical toolbox for cancer and other biomedical research
5. Researchers show beneficial role of risk calculator in fighting progression of glaucoma
6. Nonsmall cell lung cancer -- chemotherapy before surgery appears better than surgery alone
7. Trial shows circulating tumor cells predict how prostate cancer patients do with chemotherapy
8. Brain-boosting pill alleviates post-chemotherapy fogginess
9. Pre-operative chemotherapy does not increase survival rates for nonsmall cell lung cancer
10. Most pediatric chemotherapy mistakes reach patients
11. Growth factors given with chemotherapy associated with increased risk of blood diseases

Post Your Comments:
(Date:5/29/2015)... Clarkston, Metamora, Michigan (PRWEB) May 29, 2015 ... vulvar region and can cause significant physical, sexual, and ... major life altering disorder of Vulvodynia. The actual diagnosis ... Women’s Excellence in Endometriosis, they realize that this problem ... patient is experiencing any of these symptoms, they need ...
(Date:5/29/2015)... CA (PRWEB) May 29, 2015 For the ... (USAU) to bring the Denver youth ultimate community an opportunity ... learning and individual improvement. The mission of the USAU Nike ... boys and girls to improve, build character, and make lifelong ... for boys and girls of all skill and ability levels, ...
(Date:5/29/2015)... External Counterpulsation, also known as EECP ... patients. The Heart Fit Clinic is the first clinic in ... review from patients who are now completing treatment. , ... treatments of ECP treatment and received great results. His ... does the clinic perform this non-surgical treatment for heart disease, ...
(Date:5/29/2015)... An organizational consultant and part-time college professor, Dr. ... and may be suffering from early dementia. He is ... and in his uncertain relationship with his wife Addie. ... with corporate and government movers and shakers as they ... around him are being diagnosed with Alzheimer’s, Ben wonders ...
(Date:5/29/2015)... (PRWEB) May 29, 2015 Testosterone Centers of ... DFW area, is opening a new center in the Mid-Cities ... rest of the Mid Cities. Located on the south side ... in Hurst, the new testosterone center will open in May ... who suffer from low testosterone. , Like TCT’s other testosterone ...
Breaking Medicine News(10 mins):Health News:US Sports Camps, Nike Sports Camps, and USA Ultimate Host Third Summer of Ultimate Camp in Denver 2Health News:External Counterpulsation at Heart Fit Clinic Receives Raving Review 2Health News:‘Forgetful’ Professor Struggles With Dementia in Compelling New Novel 2Health News:Testosterone Clinics in Colleyville — TCT opens Hurst Location 2Health News:Testosterone Clinics in Colleyville — TCT opens Hurst Location 3
(Date:5/29/2015)... Lilly and Company (NYSE: LLY ) and AstraZeneca ... entered into a clinical trial collaboration to evaluate the ... checkpoint inhibitor, MEDI4736, in combination with CYRAMZA ® ... planned study will assess the combination as a treatment ... Phase I study is expected to establish the safety ...
(Date:5/28/2015)... 2015  Eli Lilly and Company (NYSE: LLY ) ... tender offer for up to $1.6 billion aggregate principal amount ... of notes who tendered, and did not validly withdraw, their ... City time, on May 27, 2015 (the early ... are eligible to receive the total consideration. The total consideration ...
(Date:5/28/2015)... 2015 Research and ... of Jain PharmaBiotech,s new report  "RNAi - ... offering.       (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ... involves the use of double stranded RNA ... is processed into short 21-23 nucleotide RNAs ...
Breaking Medicine Technology:Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 2Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 3Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 4Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 5Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 6Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 7Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 8Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 9Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 10Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 11Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 12Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 13Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 14Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 2Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 3Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 4Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 5Global RNAi Market Report 2015-2024 - Technologies, Markets and Companies 2Global RNAi Market Report 2015-2024 - Technologies, Markets and Companies 3
Cached News: